As shown in Figure 3C-3E, both the compounds stimulated CARP-1 expression, activation of SAPKs, PARP cleavage, and loss of cyclin B1 in the Everolimus-resistant UOK262 and A498 RCC cells. This evidence concerns the gene CCAR1 and renal cell carcinoma.